Editorial and Viewpoint
Cardiac Imaging in the Post-ISCHEMIA Trial Era: A Multisociety Viewpoint

https://doi.org/10.1016/j.jcmg.2020.05.001Get rights and content
Under an Elsevier user license
open archive

Key Words

clinical trials
ischemia
stable coronary disease

Cited by (0)

Dr. Bucciarelli-Ducci is supported in part by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health and Social Care. This work was funded in part by the Division of Intramural Research, National Heart, Lung and Blood Institute, Department of Health and Human Services. Drs. Murthy and Ruddy are currently President and Immediate Past President of the Cardiovascular Council of the Society of Nuclear Medicine and Molecular Imaging. Dr. Murthy owns stock in General Electric and Cardinal Health and stock options in Ionetix; has received consulting fees from Ionetix and Curium; has received payment for expert witness testimony from Jubilant Draximage; has received nonfinancial research support from INVIA Medical Imaging Solutions; and has served as the principal investigator on grants from the National Heart, Lung, and Blood Institute (R01HL136685) and the National Institute on Aging (R01AG05972). Dr. Ruddy has received grants from General Electric Healthcare and Advanced Accelerator Applications. Dr. Dilsizian is President of the Society of Nuclear Medicine and Molecular Imaging. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Imaging author instructions page.